Related studies have found that AML progression from JAK2-mutant (JAK2-mut) myeloproliferative neoplasms (MPN) (after MPN AML) has a poor prognosis, and the BCL-XL is overexpressed in the cells of patients with JAK2-mut MPN [117]. This evidence concerns the gene BCL2L1 and myeloproliferative neoplasm.